Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
ANI Pharmaceuticals Inc | ANIP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
66.14 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 36.99 - 70.81 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 66.14 | USD |
ANI Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.39B | 21.08M | - | 486.82M | 17.15M | 0.81 | 81.27 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ANI Pharmaceuticals News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ANIP Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 65.56 | 66.90 | 64.20 | 65.34 | 139,181 | 0.58 | 0.88% |
1 Month | 69.85 | 70.31 | 64.20 | 67.04 | 150,186 | -3.71 | -5.31% |
3 Months | 54.53 | 70.81 | 54.39 | 65.31 | 148,765 | 11.61 | 21.29% |
6 Months | 57.03 | 70.81 | 48.14 | 59.13 | 156,446 | 9.11 | 15.97% |
1 Year | 40.53 | 70.81 | 36.99 | 57.32 | 150,896 | 25.61 | 63.19% |
3 Years | 32.225 | 70.81 | 22.31 | 46.43 | 117,558 | 33.92 | 105.24% |
5 Years | 69.54 | 86.96 | 22.31 | 48.75 | 113,656 | -3.40 | -4.89% |
ANI Pharmaceuticals Description
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Propafenone, and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States. |